RBC Capital Markets thinks CSL is a bargain at current levels. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool ...

The Australian sharemarket added 25.20 points or 0.29 per cent to 8,720.80, while the broader All Ordinaries gained 28.50 points or 0.32 per cent to 9,046.50. The technology sector advanced 1.72 per ...

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here's why 2026 could look better. CSL experienced a challenging 2025 with shares underperforming the ASX 200 due to ...

Australia's CSL, which earlier this year paused plans to put its CSL Seqirus vaccine division up for sale, has opened the doors to a new $1 billion cell-based influenza vaccine and antivenom ...

Forget one of one: this particular BMW 3.0 CSL is, quite literally, the very first M race car, and it’s up for sale for presumably many dollars. The very first official BMW M project was the 3.0 CSL.

Australia’s largest drugmaker CSL Ltd. is committing roughly $1.5 billion to expand its US manufacturing footprint, joining a wave of pharmaceutical giants doubling down on American production. The ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

SYDNEY, Oct 28 (Reuters) - Australian biotech CSL (CSL.AX), opens new tab has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu ...

SYDNEY--Shares in Australia-based pharmaceutical company CSL tumbled 15% on Tuesday after the company delayed the spinoff of its flu vaccine unit and cut annual guidance. In late morning trade Tuesday ...

A rare 2023 BMW M4 CSL with only 1,600 miles is up for sale on Bring a Trailer. This lightweight, high-performance coupe looks almost new and demands attention. The Ultimate Driving Machine never ...

CSL pays $117 million for exclusive option to acquire VarmX VarmX could receive up to $388 million if milestones are met CSL funds VarmX's Phase 3 trial for VMX-C001 Sept 16 (Reuters) - Australia's ...

Joy Linton, Chief Financial Officer of Australia's biotech company CSL talks about the company's restructuring, the impact of U.S. tariffs and currency volatility risks. Got a confidential news tip?